Pfizer and BioNTech complete submission to European Medicines Agency for Omicron BA.1 Adapted Bivalent Vaccine Candidate. Company previously announced safety, tolerability, and immunogenicity data from a Phase 23 trial that found a 30ug booster dose of the vaccine elicited a superior immune response.
🌍 BioNTech SE (BNTX) - Form 6-K Filing
Filing Date: 2022-07-19
Accepted: 2022-07-19 17:12:44
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: